Neurocrine’s Phase II Results In Schizophrenia Mixed, But Enough To Move To Phase III

Competing against Bristol and AbbVie in the muscarinic receptor agonist space, Neurocrine’s drug shows efficacy but a high placebo response and no dose effect.

PS1911_Clinical Trial_1444423208_1200.jpg
Neurocrine's Phase II schizophrenia trial yielded signs of efficacy but mixed results

Opinions on Neurocrine Biosciences, Inc.’s top-line Phase II data for schizophrenia candidate NBI-1117568 were anything but clear cut on 28 August, as the company expressed strong optimism about the data on a same-day call, but its share price fell sharply. Analysts called the data disappointing yet viable for advancing the candidate into Phase III.

Key Takeaways
  • Neurocrine showed efficacy with its selective M4 agonist NBI-1117568 in schizophrenia, but only with the lowest dose tested.

  • Analysts questioned the drug’s viability against competitors from BMS and AbbVie that seem to offer better efficacy, while investor doubts led to a 19% share price drop for Neurocrine

The San Diego biotech’s selective muscarinic M4 receptor agonist met its primary endpoint of placebo-controlled change from baseline in the Positive and Negative Syndrome Scale (PANSS), but only the smallest of the four doses in the 210-patient study demonstrated efficacy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Boehringer’s Next Generation IPF Drug Underwhelms

 

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By 

The German biotech has been forced into insolvency and NASDAQ suspension.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By 

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

More from R&D

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By 

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 

Shares are hit as German conglomerate lowers revenue forecast.